Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against Notoedres cati mange in cats

The therapeutic efficacy against notoedric mange of a topical combination of esafoxolaner, eprinomectin and praziquantel (Nexgard(®) Combo, Boehringer Ingelheim) was evaluated in a masked, controlled clinical study including 14 cats with natural or induced Notoedres cati infestation. Cats were allocated randomly to two groups of seven cats each, to be administered either mineral oil (placebo control) or NexGard(®) Combo. Each treatment was administered once as spot-on at 0.12 mL per kg body weight (representing the minimum label dosage of NexGard(®) Combo, i.e. 1.44 mg esafoxolaner, 0.48 mg eprinomectin, and 10.0 mg praziquantel per kg body weight). Live mites were counted in skin scrapings collected within seven days prior to and 14, 27/28, 42 and 56 days after treatment to calculate the percentage efficacy of NexGard(®) Combo based on the comparison of mean live mite counts of the two groups. Concurrently, mange lesions and clinical signs were scored to establish a clinical success valuation. No live mites were recovered from any NexGard(®) Combo-treated cats post-treatment, indicating 100% therapeutic efficacy following a single spot-on administration of the novel antiparasitic combination. The clinical success valuations in the NexGard(®) Combo-treated cats were 14.3%, 42.8%, 100% and 100% at 14, 27/28, 42 and 56 days after treatment, respectively. No health problems were observed throughout the study.